Skip to content

Episealer® Knee

The only individualised implant for focal cartilage lesions in the knee

Learn more

Episealer® Talus

Personalised implant for osteochondral lesions in the ankle

Learn more

Episealer® Patellofemoral System

For patients with osteoarthritis of the patellofemoral joint

Learn more

The Episurf Process

To ensure you receive the best possible treatment for your cartilage lesion, every step in the process focuses on you.

MRI Scan
To obtain a clear image of the lesion and your knee, 2D and 3D MRI scans are taken
Damage Marking Report
These images are then used to create a virtual 3D model and visualisation of your knee joint
Episealer
This 3D model is the basis for the design of your individualised Episealer implant

Episealer Products

Patient testimonials

Press releases and financial reports

Episurf Medical publishes interim report for January–June 2026

Episurf Medical AB (publ) (Nasdaq: EPIS B) today publishes its interim report for January–June 2026. Rental income increased by 257 per cent to SEK 17.5 (4.9) mn. At the end of the period, the property portfolio comprised 39 (1) properties with a lettable area of 61,456 (4,529) square metres and a market value of SEK 946 (108) mn. The period in brief Rental income amounted to SEK 17.5 (4.9) mn for the half-year and SEK…

Episurf accelerates its transformation into a pure-play property company and concludes the strategic review of the medtech operations

Episurf Medical AB (publ) ("Episurf" or the "Company") is accelerating its transformation into a pure-play property company and will going forward concentrate the Company's resources and capital allocation on the Nordic property operations. As part of this, the board of directors has, within the framework of the previously communicated dual-track process, resolved to initiate an orderly wind-down of the operational medical technology business. The Company assesses that a sale or spin-off of the business in…

    Episurf Medical enters into a letter of intent regarding the acquisition of a property portfolio with an agreed property value of approximately SEK 505 mn

    Episurf Medical AB (publ) (“Episurf” or the “Company”) has today entered into a letter of intent regarding the acquisition of all shares in five property-owning companies. The agreed underlying property value amounts to approximately SEK 505 mn before deduction for deferred tax. The parties’ objective is to enter into a final share purchase agreement no later than 30 September 2026, with completion planned for around 1 November 2026. The portfolio consists of five modern, newly…